Candel Therapeutics, Inc.

NasdaqGM:CADL Stock Report

Market Cap: US$585.4m

Candel Therapeutics Management

Management criteria checks 2/4

Candel Therapeutics' CEO is Paul-Peter Tak, appointed in Sep 2020, has a tenure of 5.67 years. total yearly compensation is $4.95M, comprised of 15% salary and 85% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $2.15M. The average tenure of the management team and the board of directors is 4.2 years and 6.6 years respectively.

Key information

Paul-Peter Tak

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage15.03%
CEO tenure5.7yrs
CEO ownership0.4%
Management average tenure4.2yrs
Board average tenure6.6yrs

Recent management updates

Recent updates

Seeking Alpha • Apr 21

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling

Summary Candel Therapeutics, Inc. seems positioned for significant upside as its lead asset, aglatimagene, nears key prostate cancer Phase 3 readouts and a potential BLA filing. CADL's aglatimagene has demonstrated statistically significant improvements in disease-free survival and safety, supporting a strong case for FDA approval and commercial launch in 2027. Recent analyst price targets ($26–$30) and market excitement reflect confidence in CADL's late-stage pipeline, especially given the $2.9bn peak revenue estimate for aglatimagene. CADL’s robust cash position funds operations into Q1 2028, but commercial execution and payer adoption remain critical risks to monitor post-approval. Read the full article on Seeking Alpha
Seeking Alpha • Feb 20

Candel Therapeutics: Entering Its Pivotal Year

Summary Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. CAN-2409's Phase 2a pancreatic cancer study could be released this quarter, and its prostate cancer drug could see an FDA submission mid-year. The shorts have melted away, and the ticker is seeing strong price action. Big risks remain due to its negative EPS and debt ratios, but that potential FDA approval and its varied proprietary platforms make Candel an attractive acquisition target. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Summary Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in cash, facing a likely equity raise soon due to high operational expenses and limited cash runway. Despite a phase 2b trial setback in lower-risk prostate cancer, the phase 3 success supports a potential FDA submission by mid-2025. Viral therapies like CAN-2409 face commercialization challenges, but the strong phase 3 data justifies maintaining a "Buy" rating for CADL stock. Read the full article on Seeking Alpha
Seeking Alpha • Jul 01

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Summary Candel Therapeutics develops biological immunotherapies, combining anti-tumor and immune-stimulatory elements to target and destroy cancer cells. Its leading candidates, CAN-2409 and CAN-3110, show promising results in clinical trials for various cancers. CAN-2409 received multiple FDA designations, including Fast Track, Special Protocol Assessment, and Orphan Drug designation for pancreatic cancer. Unfortunately, CADL has significant financial questions, with a high cash burn rate and a short runway, which will necessitate additional funding soon, in my opinion. The company’s need to raise funds, likely through equity, may result in substantial stock dilution, leading to a "sell" rating despite promising IP. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Summary Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma. Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024. Data readouts from two other studies expected in Q4 of 2024, both of which deal with the targeting of patients with localized prostate cancer using CAN-2409. Read the full article on Seeking Alpha
Seeking Alpha • Sep 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Candel Therapeutics (NASDAQ:CADL) on Thursday said a European drug regulator committee had given a positive recommendation to grant an orphan drug designation to the company's CAN-2409 therapy for the treatment of glioma, which is a type of tumor that occurs in the brain and spinal cord. The European Medicines Agency's (EMA) Committee for Orphan Medical Products issued the positive opinion, CADL said in a statement. CAN-2409 is a genetically modified adenovirus that is currently being evaluated in multiple phase 2 and 3 trials for lung, brain, pancreatic and prostate cancers, CADL said. The EMA's orphan designation is given to medicines developed for rare, life-threatening diseases. CADL said the orphan drug designation follows a U.S. FDA fast track designation granted in June last year for CAN-2409 to be used in combination with antiviral drug valacyclovir to treat newly diagnosed glioma. CADL stock +3.7% to $3.64 in early trading.
Seeking Alpha • Sep 07

Candel Therapeutics appoints CFO, chief medical officer

Biopharmaceutical company Candel Therapeutics (NASDAQ:CADL) appointed Jason Amello CFO and Garrett Nichols chief medical officer. Amello, whose appointment is effective Sep. 21, is replacing John Canepa. Canepa has decided to pursue other interests and spend more time with his family. Amello joins from the rare disease biotech company Saniona, while Nichols joins from Istari Oncology. Source: Press Release
Seeking Alpha • Oct 21

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Candel is an immunotherapy company with a lead asset, CAN-2409, in Phase 3 clinical trials for prostate cancer. CAN-2409 has a strong clinical safety data across >700 patients and the potential to become a transformative therapy in prostate cancer. With ongoing pivotal clinical trials across 2 stages of prostate cancer along with trials in glioma and NSCLC, CAN-2409 will serve as a key catalyst for Candel. Depending on the binary event of the lead clinical trial, Candel Therapeutics will be in a position to expand CAN-2409’s use for more indications, expand the platform, and engage in more partnerships.

CEO Compensation Analysis

How has Paul-Peter Tak's remuneration changed compared to Candel Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$54m

Dec 31 2025US$5mUS$744k

-US$38m

Sep 30 2025n/an/a

-US$23m

Jun 30 2025n/an/a

-US$22m

Mar 31 2025n/an/a

-US$40m

Dec 31 2024US$1mUS$689k

-US$55m

Sep 30 2024n/an/a

-US$52m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$1mUS$670k

-US$38m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$2mUS$670k

-US$19m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$957kUS$545k

-US$36m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$3mUS$135k

-US$18m

Compensation vs Market: Paul-Peter's total compensation ($USD4.95M) is above average for companies of similar size in the US market ($USD2.64M).

Compensation vs Earnings: Paul-Peter's compensation has increased whilst the company is unprofitable.

CEO

Paul-Peter Tak (64 yo)

5.7yrs
Tenure
US$4,947,909
Compensation

Dr. Paul-Peter Tak, M.D. PH.D. FMEDSCI, has been Member of Advisory Board at SecondWave Systems, Inc. from March 2024. He serves as President & Chief Executive Officer at Candel Therapeutics, Inc. since Se...

Leadership Team

NamePositionTenureCompensationOwnership
Paul-Peter Tak
President5.7yrsUS$4.95m0.37%
$ 2.1m
Charles Schoch
Senior VP2.3yrsUS$1.24m0.059%
$ 346.7k
Francesca Barone
Chief Scientific Officer4.3yrsUS$1.36m0.14%
$ 805.5k
Seshu Tyagarajan
Chief Technical & Development Officer4.1yrsUS$613.23k0.12%
$ 726.0k
Ileen Winick
Chief People Officerno datano datano data
Susan Stewart
Chief Regulatory Officer5.6yrsno datano data
William Garrett
Chief Medical Officer3.7yrsno data0.072%
$ 419.4k
4.2yrs
Average Tenure
56.5yo
Average Age

Experienced Management: CADL's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul-Peter Tak
President5.7yrsUS$4.95m0.37%
$ 2.1m
Edward Benz
Member of Research Advisory Board & Independent Director8.7yrsUS$103.55k0%
$ 0
Paul Manning
Independent Chairman7.5yrsUS$130.55k6.07%
$ 35.5m
Scott Eggener
Member of Scientific Advisory Boardno datano datano data
Adam Kibel
Member of Scientific Advisory Boardno datano datano data
E. Chiocca
Member of Scientific Advisory Boardno datano datano data
Renee Gaeta
Independent Director3.8yrsUS$103.05k0%
$ 0
Christopher Martell
Independent Director7.5yrsUS$114.55k0.75%
$ 4.4m
Charu Aggarwal
Member of Scientific Advisory Boardno datano datano data
Steven Albelda
Member of Scientific Advisory Boardno datano datano data
Mark Bloomston
Member of Scientific Advisory Boardno datano datano data
Nicoletta Loggia
Independent Director2.9yrsUS$107.02k0.0029%
$ 17.1k
6.6yrs
Average Tenure
60.5yo
Average Age

Experienced Board: CADL's board of directors are considered experienced (6.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 11:07
End of Day Share Price 2026/05/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Candel Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Alec StranahanBofA Global Research
Brian Kemp DolliverBrookline Capital Markets